Three year IGF-I treatment of children with Laron syndrome.

Abstract

Nine prepubertal children with Laron syndrome (6 males, 3 females) aged 0.5 to 14.6 years were treated by daily subcutaneous injections of IGF-I in doses of 150-200 micrograms/kg. All patients completed at least one year of treatment; six completed two years and five three years. During the first year, a significant increase in linear growth velocity, from a mean +/- SD of 4.7 +/- 1.3 to 8.2 +/- 0.8 cm/yr (p < 0.0001), was registered. In the second year the growth velocity was lower, but still significantly higher than before treatment. Bone maturation advanced proportionally with chronological age. A reduction in subcutaneous fat tissue was observed despite the body weight increase. There was no aggravation of the characteristic hypoglycemic episodes; on the contrary, there was a better tolerance to fasting. Significant increases in serum alkaline phosphatase, phosphorus and procollagens were registered throughout the study. In conclusion, IGF-I provides an effective replacement treatment for IGF-I-deficient children, mimicking most effects ascribed to growth hormone.

• Authors: B Klinger, Z Laron
• Journal: Journal of pediatric endocrinology & metabolism : JPEM (J Pediatr Endocrinol Metab) 1995 Jul-Sep Vol. 8 Issue 3 Pg. 149-58 ISSN: 0334-018X [Print] Germany
• PMID: 8521188 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Recombinant Proteins
• Insulin-Like Growth Factor I
• Growth Hormone

Topics

• Adolescent
• Body Height (physiology)
• Body Weight (physiology)
• Bone Development (drug effects, physiology)
• Bone and Bones (metabolism)
• Child
• Child, Preschool
• Female
• Growth Disorders (metabolism, pathology, therapy)
• Growth Hormone (physiology)
• Heart Rate (physiology)
• Humans
• Infant
• Injections, Subcutaneous
• Insulin-Like Growth Factor I (deficiency, therapeutic use)
• Male
• Recombinant Proteins (therapeutic use)
• Skinfold Thickness
• Syndrome
• Time Factors